Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ...

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous ...

The MarketWatch News Department was not involved in the creation of this content. Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in ...

(RTTNews) - Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in ...

Detailed price information for Acrivon Therapeutics Inc (ACRV-Q) from The Globe and Mail including charting and trades.

Stage 2 endometrial cancer spreads to the cervical stroma but remains within the uterus and cervix, requiring precise staging and diagnosis. Treatment typically involves surgery, possibly a radical ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Uterine cancer is staged using the FIGO and TNM systems based on tumor size, lymph nodes, and metastasis. Stage 1 uterine cancer may involve abnormal vaginal bleeding and is often treated with surgery ...

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...